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The Clinical Ethics Advisory Group (CEAG) at University Hospitals Bristol NHS Foundation Trust agreed 
to discuss the following case. The University Hospitals Bristol CEAG was established in 2006 and serves 
several large teaching hospitals in the South West of England. Group membership comprises 
representatives from senior and junior medical staff, nursing and midwifery, allied health and health-
care science professions, a non-executive director (lay member), a spiritual adviser and a medical 
ethicist. The CEAG provides a consultation service, education for hospital staff and offers review of 
hospital policies where ethics input is required. The Group meets quarterly, but members are also 
available at times in between to receive referrals and give advice. ‘Live’ consultations may take place at 
meetings of the group by telephone consultation between members or by email (with anonymized 
details). Cases have included end-of-life issues, use of new or experimental treatments and children's 
issues, sometimes where there has been conflict between clinicians and family. All cases and notes of 
Group deliberations are recorded and minutes are taken of every meeting.  
 
Referral to the CEAG: deriving drugs from animal sources and considerations of religion 
A 70-year-old patient of Middle-Eastern origin (Mr D) is admitted for management of exacerbation of 
obstructive lung disease. Mr D has capacity to consent to, or refuse, medical treatment. As he is likely to 
be bed-bound for several days, hospital policy (reflecting national guidance) is that he receives 
prophylactic heparin to reduce the risk of potentially fatal venous thrombosis. The standard drugs used 
for prophylaxis against blood clots are various forms of heparin, which is given via subcutaneous 
injection. All heparins are derived from pigs. A junior doctor has asked her consultant whether she 
should ask Mr D if porcine-derived heparin is acceptable to him.  
We are concerned about how we should proceed. The animal origin of some drugs may not always be 
known to staff prescribing or administering these drugs. Patients may be even less likely to have this 
knowledge. Further, information is not easily available to patients or health professionals who may wish 
to know more. For example, although the ‘Summary of Product Characteristics’ required to be published 
about any drug includes this information, it is not readily available to prescribers (particularly as Internet 
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access is not always available on the ward) and would have to be sought on each occasion that a patient 
is prescribed a new drug.  
A proportion of patients will be members of certain religious faiths that prohibit the ingestion of certain 
foods. While we need to be careful about making assumptions about whether particular patients are 
members of these faiths (and if so whether they follow its doctrines strictly), religious doctrines may be 
interpreted by some patients to extend to prohibit the ingestion or other use of pharmaceuticals derived 
from specific animals. Similar views may also be held by people who choose to follow a vegetarian or 
vegan diet.  
If we talk with Mr D and make the porcine origin of this drug known to him, he may choose to decline 
this drug. However, to not administer it would be contrary to national guidance (although within Mr D's 
legal rights) and could affect clinical outcomes. We could perhaps instead prescribe one of the newer 
clot-preventing drugs that are entirely synthetic. These may also be easier to administer and monitor, 
but are more expensive. Some may also have to be prescribed outside of the product licence, with less 
available evidence of effectiveness.  
A further issue is that the use in this case is for prophylaxis as opposed to treatment. Heparin is 
recommended to prevent a complication which, while potentially serious (including fatal), may also not 
occur at all. That said, such administration is increasingly viewed as medically essential.  
We are approaching the ethics committee with the following questions in mind:  
1. Should we feel a moral obligation to disclose the derivation of heparin to Mr D (or indeed to all 
patients)? 
2. If not, is it sufficient to honestly answer questions if he raises them? 
3. Is there a morally relevant difference between patients who object to certain animal products on 
religious grounds and those who have strong concerns about animal welfare?  
4. When considering purchasing drugs like heparin, would the ethics committee be happy to 
recommend the purchase of alternative non-animal-derived products which may be more 
expensive?  
 
Response from the University Hospitals Bristol CEAG 
Thank you for your referral, which we considered at our meeting on 14 September 2009. This case 
provides an interesting example of a general issue that arises in hospital medicine: that of administering 
drugs and disclosing the components from which they are developed. How much information should we 
be required to provide to patients about the origin of the drugs they are receiving? What other 
limitations might there be? What choices should patients be able to make, and what responsibilities do 
health professionals have?  
Background 
Hospital protocols, informed by national guidance, dictate that all inpatients should receive a 
prophylactic dose of the drug heparin. This drug has proven to be effective in reducing the chances of a 
blood clot forming during a hospital stay. However, it is produced from a porcine source. The issue that 
has arisen here is that it appears the junior doctor (and perhaps her colleague) believe Mr D may be a 
member of the Muslim faith.  
Eating certain foods is generally prohibited under Islam. This includes alcohol and pork (including 
porcine-derived gelatine) and blood; for this reason Halal meat is drained of blood. The Qur'an prohibits 
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the consumption of pork in four sections: 2.173, 5.3, 6.145 and 16.115: ‘Forbidden to you (for food) are: 
dead meat, blood, the flesh of swine and that on which hath been invoked a name other than that of 
Allah’ (Al Qur'an 5:3).  
The question therefore arises as to whether Mr D, were he to be informed about the porcine origin of 
heparin, would choose to refuse this drug. Likewise, as the referrer recognizes, the use of drugs that 
have been produced from animal products may also have implications for the increasing number of 
people who follow a vegetarian or vegan diet.  
However Islam also includes five key legal principles, of which one is that ‘necessity permits the 
impermissible’.1 To this end, if there is absolute necessity that a particular treatment course be 
followed, and there are no religiously lawful alternatives, the above Sacred Laws may be temporarily 
suspended.2 Such a suspension would usually occur following a discussion with a religious leader.3 
There is not much information about Mr D's background or what, if anything has been discussed with 
him. We have therefore assumed that as yet nothing has been disclosed to him about how this drug is 
made, although he may have been informed that it is standard procedure for him to receive a 
prophylactic dose to prevent blood clotting while in hospital. We also do not know anything about Mr 
D's attitudes to diet or indeed whether he is active in his practice as a (presumed) member of the Muslim 
faith – a point we will return to below.  
Should we feel a moral obligation to disclose the derivation of heparin to Mr D (or indeed to all 
patients)? 
Before addressing the ethical or moral aspects of this issue, our discussion first turned to a brief 
consideration of legal aspects. It is our view that, in general, we have a legal obligation to tell patients 
any information about their medical care that they would like (subject to the usual legal doctrine of 
informed consent, and its limits). However, we feel that it is less legally certain how much of a legal 
obligation we have to tell patients everything they might expect to know, as opposed to their freedom or 
responsibility to ask us specific questions for us to then answer?4 At one extreme, if we were to go into 
significant detail about drug and treatment origins with every patient, then this will have an immediate 
and detrimental impact on hospital operational procedures. On the other hand, patients may not always 
have the requisite background information they need to ask us the types of questions they would have 
done had they had more information.  
The issue of faith-based requirements to avoid ingesting certain products is, of course, not limited to the 
Muslim faith. The administration of porcine-derived products is also likely to be relevant to Jewish 
patients as well as many Hindus and Sikhs. Patients are encouraged to disclose their religious affiliation 
with their care provider and to ask about alternative drugs.5 However, patients are also informed that 
the prescribing of porcine-derived medication needs to be sensitive to their religious beliefs.6 Health 
professionals are therefore encouraged to give consideration to patient's religious beliefs before 
prescribing drugs or treatment.7–9 
We worry that this issue has not yet been discussed in a more open manner within the National Health 
Service (NHS) or with different faith groups (and vegetarian activism groups). The doctrine of consent 
has changed and developed significantly in recent decades and patients now rightly expect a great deal 
more information and consultation regarding their treatment than they did previously. Our challenge is 
to determine what individual patients might want and to meet these expectations within the limitations 
of busy hospital environments.  
In cases like these, it is also important to consider what information staff have available to them. When 
we first began to discuss this issue in our own group it came as a surprise to some that heparin was 
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produced from porcine origin. Ensuring all hospital staff have access to this information will be a 
significant undertaking. Raising expectations as to information-delivery about the ingredients and 
methods of production of all hospital medicines may place a significant drain on pharmacy resources and 
could lead to delays in administering medications as staff take extra steps to ascertain patient questions, 
obtain the necessary information, go back to the patient and allow the patient time to decide.  
Yet, despite these anticipated logistical difficulties, we feel uncomfortable about administering a drug 
that we know some of our patients might refuse were they to know its origins. While many religious 
faiths allow the administration of a variety of drugs when medical necessity dictates (such as in an 
emergency context), not all administration of these drugs occurs in this context and Mr D's case is an 
example of this. We were unsure whether prophylactic administration of heparin would be considered 
as a necessity and how the availability of alternatives would be interpreted. This needs to be taken into 
account; however, below we also raise the long-term implications of a reduction in prophylaxis in the 
hospital setting, as there is significant morbidity and mortality from hospital-acquired thrombotic events.  
For Mr D we do therefore have an obligation to discuss this with him – but this would also be an 
obligation that should extend to all patients, as we need to avoid making assumptions based on a 
particular patient's ethnic origin or other cultural factors. Such discussions should not commence from 
the premise that if Mr D is indeed a Muslim he would refuse heparin; rather, he should be presented 
with the options and allowed to make a choice. We need to be wary about making behavioural 
assumptions based on a patient's presumed faith. Mr D may or may not be a devout Muslim; he may also 
need some assistance to come to a decision about whether to take heparin.  
To summarize, our view is that we do have a moral obligation to disclose the derivation of heparin to Mr 
D and indeed to all patients to allow them to come to a considered and informed choice. We therefore 
have a responsibility to explore this in a broader way, but if we are to do this we need to be able to 
accommodate the consequences.  
If not, is it sufficient to honestly answer questions if he raises them? 
Given our answer to the first question above, it will come as no surprise that we do not believe it is 
sufficient to honestly answer questions from Mr D if he raises them. It is not up to us as health 
professionals to make a moral or faith-based judgement on behalf of our patients as to which 
medications to take and which to refuse. However, information provision is an issue. Patients with strong 
views about the content of their medicines are perhaps more likely to ‘speak up’ and receive the 
information they need. For those patients who do not ask questions, it may be paternalistic to make 
assumptions. We want to give our patients the information they need to make a considered autonomous 
choice, but we also need to be mindful of ‘overloading’ patients with too much information, not all of 
which may be wanted. We do need to take care not to upset our patients or simply transfer this problem 
on to them. This will require health professionals to take a balanced and situation-based approach and 
to be sensitive to each patient's needs and preferences.  
To adopt the approach of only answering questions as and when they are posed could also be seen to be 
‘abandoning’ our patients to rely on their own knowledge. How reasonable is it for us to expect that Mr 
D will have had access to the necessary background information he needs to ask ‘the right questions’? It 
will be important to support all patients and provide information in stages to allow reflection, 
consultation with others and decision-making. However in so doing, the importance of heparin (including 
its prophylactic use) should be emphasized.  
Is there a morally relevant difference between patients who object to certain animal products on 
religious grounds and those who have strong concerns about animal welfare?  
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Our view is that there is no morally relevant difference between these groups. As we have discussed 
above, it will be important not to make general assumptions about patients' religious or other beliefs 
based on their ethnic or cultural background. It should not matter whether the basis for this objection is 
based on religious or animal welfare considerations.  
There does, however, need to be further consultation with religious and other interested groups to 
ensure that wider population education can take place; a point we return to below.  
When considering purchasing drugs like heparin, would the ethics committee be happy to recommend 
the purchase of alternative non-animal-derived products which may be more expensive?  
A Trust may show some resistance to this kind of information being routinely provided to patients, for 
two reasons. First, Trusts may be likely to emphasize the importance of prophylactic heparin for the 
safety of inpatients, as an increase in refusal of these drugs may detrimentally impact patient outcomes. 
Second (and more relevant to the question posed), wide refusal could also mean that a Trust would need 
to look at alternative, but more expensive, drugs to be administered instead of heparin. The synthetic 
forms of heparin are about one and a half times as expensive as the porcine-derived version – which if 
widely adopted would increase this drug budget by at least 50%. If all patients elected to take this form, 
this could impact on other aspects of patient care.  
However, the synthetic forms of these drugs may also offer some clinical advantages. From a clinical 
perspective, it may actually be better to give all patients (whatever their attitudes or beliefs) the newer 
form of this drug. If we provide this information to all patients in conjunction with the information about 
animal origins, many more may want to take the newer, synthetic and potentially more effective form. 
The question is the amount of information we have the obligation to provide: animal origins only, or 
clinical effectiveness?  
It is also, of course, within Mr D's right to refuse to take any form of prophylactic drug, even if this would 
go against what is in his best interests. However, a right to refuse treatment is not the same as a right to 
demand a particular treatment and in a system of nationalized health-care rationing is always going to 
be necessary. Yet if we are to ration non-animal-derived heparin, is it acceptable to ration it to particular 
groups on moral or religious grounds? This would seem to constitute rationing based on religious as 
opposed to medical interests. The hospital pharmacist could therefore look at the availability of a wide 
variety of drugs to prescribe as alternatives.  
The approach to prophylaxis within the NHS has been to offer a porcine-derived drug. However, the NHS 
has recently begun to allow patients to privately ‘top up’ the cost of their medicines through choosing 
and paying for medicines not routinely available within NHS budgets. The practice, which began in 
oncology, is in itself controversial, but a detailed discussion of the issues goes beyond the scope of this 
case.10 Here the reason for private top-up will predominantly be due to drug origin rather than drug 
effectiveness – should this make a difference? If the non-porcine version of the drug costs the same, 
then the Trust may choose to purchase it, whereas in oncology the problem is more that the National 
Institute for Health and Clinical Excellence has not approved the drug for NHS use.  
If a Trust or PCT cannot afford an increased drugs bill to cover synthetic forms of heparin then problems 
may arise. If the medicines or formulary committee vetoes the purchase of synthetic heparin but patient 
refusals of the animal-derived form increase, problems could arise such as surgeons refusing to operate 
if no prophylaxis has been taken. So we do need to think about the long-term implications of providing 
patients with enhanced information about animal origins of drugs.  
 
Conclusion 
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In discussing Mr D's case, the position we have come to is that when obtaining consent to administer 
heparin, the health professional treating him needs to ask him whether he has any objections to the use 
of drugs derived from animals. Such a request would not be based on him being a 70-year-old male of 
Middle-Eastern origin, but because he is a patient in hospital. This kind of information provision should 
form part of the work-up for all hospital patients. This approach will obviously have resource 
implications, but if incorporated into a general approach of openness and information provision, it 
should be possible to build such a discussion into routine care as much as possible. This would 
encompass providing information including the availability (or lack thereof) of alternative products and 
allow Mr D to make a choice according to his beliefs. This decision should then be recorded in Mr D's 
notes, or a space could be created in drugs charts to record this information.  
We have come to this decision because we do not believe it is appropriate to let the status quo prevail. 
Changes to models of good practice in patient consent and information provision, as well as an 
increasingly multi-faith and multi-perspective society, mean we need to reconsider this non-provision of 
information. Of course, it may be that some followers of the Muslim faith feel comfortable taking 
heparin. Indeed, the animal origin of heparin may be more of an issue for patients who follow a 
vegetarian or vegan diet. Wider awareness of the animal origin of heparin may also lead to wider refusal 
of it in the patient population. However, we cannot make these assumptions and the principle of giving 
information is arguably no different depending on whether it is grounded in legal, philosophical or 
religious tenets. Further investigations, together with greater transparency for patients, are warranted. 
The challenge is to find a way to provide this information in a balanced and supportive way and to offer 
patients a real choice.  
This problem could perhaps be partially resolved by developing initiatives such as information leaflets. 
For example, our Trust is considering adding a statement to patient leaflets about medicines stating that 
some drugs may be of animal origin. However, the logistics of ensuring these reach all patients in a 
timely manner are challenging, particularly the timing of leaflet provision as not all patients will know in 
advance that they are going to be in hospital. Moreover, the content of such leaflets may be difficult to 
determine: if a patient is told that ‘some of your medicines’ may contain animal products, in practice if a 
patient is taking several medications this may give rise to more questions. Informing patients who are 
unconscious or in other emergency contexts will also be difficult. It will not always be possible to assess 
patient needs and preferences in advance and sometimes assumptions will need to be made. That said, a 
leaflet-based approach does go some way to begin to address this problem – particularly if there is a 
considered approach to leaflet development and perhaps specialist materials for members of particular 
groups developed with full consultation.  
It will also be vital to educate Trust staff about this issue to ensure that all know that this may be a 
problem. In our own Trust this issue has already been the subject of a Grand Round, and Trust 
pharmacists will also know the composition of most common drugs (as well as being able to determine 
this for all other drugs). A list of the most common drugs that are animal-derived could also be 
developed, which could then be used as a ‘checklist’ to trigger a request for more information such as 
one of the leaflets described above. These could be made available on the Trust intranet. Issues around 
animal origins of drugs are also amenable to Trust audits and such practices should be encouraged.  
The diversity of approaches to product origins within religious faiths is increasingly being complemented 
by the escalating prevalence of vegetarianism and veganism, as well as a general upsurge in societal 
interest as to the origins and safety of all consumer products, including foods and medicines. Therefore, 
there now needs to be a national focus to develop initiatives to help patients make considered and 
autonomous choices about consenting to take certain drugs. Health professionals and the NHS need to 
work with faith and activist organizations to help both ourselves and patients make these decisions. 
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Some initial reactions from these groups are given in Boxes 1 and 2. Working together in this way will 
help us determine how best to respond to all patients for whom the animal origin of their drugs will be a 
relevant consideration to taking them.  
 
Box 1 Comment from the Muslim Council of Britain 
Dr Shuja Shafi, Chair of Muslim Spiritual Care Provision in the NHS at the Muslim Council of Britain, said:  
The MCB continues to work together with health professionals and the pharmaceutical industry to try to 
increase awareness of this important issue. It is our view that any prescription of porcine-derived 
medication should be sensitive to the individual's religious background. Taking porcine-derived products 
into the body (by whatever means) is prohibited in Islam. Health-care professionals should, therefore 
ensure that all patients are made aware if a drug prescribed to them contains animal products so that 
they have the opportunity to ask for alternatives. However, in the absence of suitable alternatives, 
religious leaders can exempt medicines when there is medical necessity. Given that prophylactic heparin 
is prescribed as a medical necessity, the same principle is applicable. The MCB encourages Muslim 
patients who wish to discuss this matter to seek advice from their local Muslim Healthcare Chaplain 
(Imam). The MCB also encourages NHS Trusts to educate their employees about the importance of 
communicating this information to all patients and to consider making non-porcine anti-clotting and 
other medications available to those patients who, having considered the alternatives, wish to avoid 
porcine-derived heparin. The pharmaceutical industry should be urged to consider seeking alternatives to 
animal-based medications.  
 
Box 2 Comment from the Vegetarian Society 
Annette Pinner, Chief Executive of the Vegetarian Society, stated: 
We very much welcome this issue being raised. The Vegetarian Society receives a lot of queries from 
vegetarians who need to make a decision about whether to accept various drugs, vaccines or blood 
products when those products may comprise ingredients that are animal-derived. Strictly speaking, 
vegetarianism is related to diet and eating. However, many vegetarians choose to take this further and 
decide to apply the principles of vegetarianism to the medications they take or the clothing they wear. 
This is therefore an important issue; not only because it is derived from people's personal beliefs but 
because there may also be legal implications, for example under the Equality Act. It is our view that 
information about the origins of drugs used in health-care treatment must be made available to all 
patients, to help them make an informed choice about which medications they choose to take. This 
responsibility lies with both the companies who manufacture and market the various drugs involved but 
also the National Health Service. We look forward to further discussion on this important topic. 
 
Members of University Hospitals Bristol NHS Foundation Trust CEAG who discussed this case 
Jane Buswell, Nurse Consultant, Older People; Chris Davies, Head of Spiritual & Pastoral Care; June Dyer, 
Clinical Nurse Specialist in Cystic Fibrosis; Dr Ruth Evans, GP Registrar; Professor Karen Forbes, 
Consultant in Palliative Medicine; Kevin Gibbs, Pharmacist; Phil Hall, Assistant Director, Medical Director 
Team (Committee Administrator); Dr Ian Jenkins, Consultant in Paediatric Intensive Care and 
Anaesthesia; Dr Sally Masey, Consultant Anaesthetist (Chair); Ms Peggy Woodward, Midwife; and Sue 
Yarrow, Superintendent Radiographer.  
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Also in attendance: Dr Philip Segar, Consultant Paediatric Anaesthetist; Dr Terri Rotchell, GP Trainee. 
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